Koru Medical Systems, Inc. · NASDAQ:KRMD
Koru Medical Systems — Q1 2025 Earnings Presentation
17 slides from Koru Medical Systems's earnings presentation, May 7, 2025
Slide 1: KORU Medical Systems Q1 2025 Earnings Call
KORU Medical Systems Q1 2025 Earnings Call May 7, 2025 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to,
Slide 3: Strong First Quarter Results Highlight Strategic Progress
Q1 2025 Results Strong First Quarter Results Highlight Strategic Progress 1 Q1 revenues of $9.6 million, 18% growth over the prior year period Core business growth of 21% driven by recurring revenues, new patient starts, share expansion, and geographic 2 expansion 3 Announcing plans to submit for FD
Slide 4: KORU's Vision for Accelerated Expansion
Our Company KORU’s Vision for Accelerated Expansion More Time For What Matters Most KORU’s Freedom Infusion System is a leader in large- volume (>10mL) drug delivery Capitalizing on the ongoing shift from intravenous (IV) hospital settings to subcutaneous (SC) therapy in the home and in infusion cli
Slide 5: Strong Execution Across All Three Strategic Growth Pillars
Q1 2025 Results Strong Execution Across All Three Strategic Growth Pillars Defend and Grow New Drugs on Label Through Leadership Position in Expand Internationally Pharmaceutical Services and Domestic SCIg Core Clinical Trials (PST) Domestic Core performance International Core performance 15 pharma
Slide 6: Recurring Revenues Supported by Strong Underlying SCIg Market Growth
Future Catalysts Recurring Revenues Supported by Strong Underlying SCIg Market Growth KORU Recurring Revenue KORU Non-Recurring Revenue Strong Recurring Base that is Expected to Grow $33.6M Total $28.5M Total ~75% of KORU’s revenue is recurring Removing initial 1x sale of pumps and Novel Therapies s
Slide 7: Rapidly Expanding International Business
Future Catalysts Rapidly Expanding International Business Rapidly Expanding International Robust Growth Since Inception of International Core Strategy Market Opportunity Net International Revenues; Top-10 markets remain under penetrated In Millions Significant growth potential in key regions $60M Ad
Slide 8: Robust Pipeline With Multiple Near-Term Opportunities
Future Catalysts Robust Pipeline With Multiple Near-Term Opportunities 17 Opportunities / 15 Collaborations 9 Commercial Opportunities by 2026 $2.7B1 Addressable Market Combined Immunology New Indications/New Devices Drug Trial Expected KRMD Patient Population Asset Phase Next Step Clearance2 (000s)
Slide 9: Q1 Y/Y Revenue by Business
Financials Q1 Y/Y Revenue by Business Net Revenues; In Millions Domestic Core • Increased 16% y/y • Outpaced SCIg market growth • Driven by new patient starts, market share gains, $9.6 and strong pump volumes $0.3 $8.2 18% International Core $2.4 • Increased 36% y/y $0.5 • Expanded into new geograph
Slide 10: Q1 Gross Margin Profile
Financials Q1 Gross Margin Profile Driving y/y Margin Improvement with Gross Margin Consistent Performance >60% First Quarter: 62.8% • 50 basis points improvement y/y 63.4% 50 bps • Driven by favorable product sales 61-63% 62.8% mix 62.3% • Continue to implement operational excellence programs to ex
Slide 11: Q1 Cash Balance
Financials Q1 Cash Balance Cash Balance as of March 31, 2025: $8.7M Key Drivers Q1 cash usage of $0.8M • Net loss of ~($1.2M)/ 36% $9.6M improvement +$0.9M $8.7M • Investments ($0.4M) in capex for ($1.2M) next generation consumables ($0.6M) ($0.1M) production line, and insurance premium financing ($
Slide 12: Raising 2025 Revenue Guidance
Outlook Raising 2025 Revenue Guidance Revenue Gross Margin Cash Flow Growth Profile Generation Increased to Reiterated between Reiterated positive $38.5-$39.5M, 61-63% cash flow from 15-17% growth operations for the full year 2025 Key Drivers/Milestones Key Drivers/Milestones Key Drivers/Milestones
Slide 13: Key 2025 Milestones
Outlook Key 2025 Milestones Financial Targets and Guidance • $38.5-39.5M ; mid teens growth • Positive cash flow from operations for FY2025 • Adj. EBITDA growth, higher gross profit, increased operating leverage Add New Drugs to Label through Novel Therapies Pipeline • 3 new pharmaceutical collabora
Slide 14: Sustained pathway to +20% growth
Outlook Sustained pathway to +20% growth Key Growth Drivers Sustained share of SCIg market growth and share gains 8-10% annual growth New business development New drugs New product launches & innovation on label 2nd generation consumables, new PFS pump, and flow controller International expansion (T
Slide 15: Strategic Highlights Summary
KORU Medical Strategic Highlights Summary Macro tailwinds driving adoption of subcutaneous therapy; many large-volume 1 SC drugs in development by major Pharma companies in multiple indications 2 21% growth in Core business with 75% recurring revenues Strong underlying SCIg market; gaining greater m
Slide 16: Appendix
Appendix 16
Slide 17: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by othe